Delivery Order SPE2DB24D2205-SPE2DB24FEAPS

Award Date 9/28/24
Potential Completion Date 9/30/24
Potential Value $50K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $11,583.43, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, a Delivery Order, is for the supply of DUPIXENT 300 MG/2 ML PEN 2ML, a prescription medication. The contract has a firm fixed price and an ultimate completion date of June 3, 2024. The award is associated with a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds...
This federal contract award, valued at $3,418.92, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This...
This federal contract award, valued at $11,566.45, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, a specialty pharmaceutical product, to support federal healthcare programs. The award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at $999,999,999 and...
This federal contract award, valued at $22,469.93, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the supply of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product, to support military healthcare programs. The contract is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at...
This federal contract award, valued at $8,933.69, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product, with a performance period through March 18, 2025. The award is part of a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at $999,999,999...
This federal contract award, valued at $13,498.76, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of DUPIXENT 300 MG/2 ML PEN 2ML. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 through December 2025, which enables the DLA Troop Support Medical to efficiently procure a comprehensive range of medical commodities from Amerisourcebergen to support...
This federal contract award, valued at $6,765.93, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, a medication likely used for various medical treatments. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running...
This federal contract award, valued at $12,339.80, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, a specialty pharmaceutical product. The contract is a delivery order and is priced on a firm fixed-price basis. It has an ultimate completion date of May 12, 2023. This award is part of a larger Indefinite Delivery Contract (IDC)...
This federal contract award, valued at $100,378.46, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, a medical product, with an ultimate completion date of January 7, 2025. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop...
This federal contract award, valued at $34,699.35, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of DUPIXENT 300 MG/2 ML PEN 2ML, a specialty medication, to support military treatment programs and facilities. The contract has a completion date of September 20, 2024 and is a firm fixed-price delivery order. This award is part of a larger Indefinite Delivery Contract (IDC) between...
  • SPE2DB24D2205
    Indefinite Delivery Contract
  • SPE2DB24D2205-SPE2DB24FEAPS
    Delivery Order

This federal contract award, valued at $49,574.56, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of DUPIXENT 300 MG/2 ML PEN 2ML, a specialty medication, to support various government healthcare programs.

The award is a delivery order under an Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025. This IDC enables the DLA to efficiently procure a comprehensive range of pharmaceutical and medical commodities from Amerisourcebergen to support military treatment facilities and other federal healthcare providers nationwide. The contract does not have a set-aside designation and is expected to be completed by September 30, 2024.

Generated 12/28/24, 9:21 AM